0001171843-24-004562.txt : 20240808 0001171843-24-004562.hdr.sgml : 20240808 20240808082940 ACCESSION NUMBER: 0001171843-24-004562 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HARVARD BIOSCIENCE INC CENTRAL INDEX KEY: 0001123494 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043306140 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33957 FILM NUMBER: 241186223 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL RD CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: 5088938999 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD CITY: HOLLISTON STATE: MA ZIP: 01746 8-K 1 f8k_080824.htm FORM 8-K Form 8-K
false 0001123494 0001123494 2024-08-08 2024-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

 

FORM 8-K

_________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 8, 2024

_______________________________

 

 

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

______________________________

 

 

Delaware 001-33957 04-3306140
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

84 October Hill Road

Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

 

(508) 893-8999

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

____________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value HBIO The NASDAQ Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 8, 2024, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three months ended June 30, 2024, and the details of a related conference call to be held at 10:00 AM ET on August 8, 2024. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

 

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01. Financial Statements and Exhibits.

 

 

(d) Exhibits.

 

Exhibit Number   Description
     
99.1   Press Release issued by Harvard Bioscience, Inc. on August 8, 2024
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  HARVARD BIOSCIENCE, INC.
   
Date: August 8, 2024 By: /s/ Jennifer Cote                     
    Jennifer Cote
    Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 EX-99.1 2 exh_991.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Harvard Bioscience Announces Second Quarter 2024 Financial Results

 

HOLLISTON, Mass., August 8, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024.

 

Jim Green, Chairman and CEO, said, “Second quarter revenues reflect a more challenging than expected market environment. With the uncertainty of the timing for market recovery we stayed focused on managing costs and the actions we implemented during Q2 are expected to drive annualized savings of approximately $4 million while we continue our work on new product development and growth initiatives.”

 

Green continued, “We believe the market recovery is likely delayed to later in the second half however we remain excited about the long-term growth prospects from our innovative new products.”

 

Financial Results Summary  Three Months Ended June 30,   Six Months Ended June 30, 
(unaudited, $ in millions except per share data)  2024   2023   2024   2023 
Revenues  $23.1   $28.8   $47.6   $58.7 
Gross margin   57.2%   58.0%   58.8%   59.6%
Operating (loss) income (GAAP)  $(2.1)  $0.8   $(4.3)  $2.5 
Adjusted operating income  $0.8   $3.6   $2.0   $8.0 
Net loss (GAAP)  $(2.9)  $(1.0)  $(7.6)  $(0.4)
Diluted loss per share (GAAP)  $(0.07)  $(0.02)  $(0.18)  $(0.01)
Diluted adjusted (loss) earnings per share  $0.00   $0.04   $0.02   $0.09 
Adjusted EBITDA  $1.3   $3.9   $2.9   $8.7 
Adjusted EBITDA margin   5.5%   13.6%   6.1%   14.7%
Cash flow provided by operations            $0.6   $5.4 

 

This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

 

Second Quarter 2024 Results

 

For the second quarter of fiscal 2024, the Company reported revenues of $23.1 million compared to $28.8 million in the second quarter of fiscal 2023. Gross margin for the three months ended June 30, 2024 was 57.2% compared with 58.0% in the comparable quarter of the prior year. Gross profit was $13.2 million for the second quarter of 2024 compared to $16.7 million in the same period last year. Gross margin below the Company’s target of 60% was primarily due to lower absorption of fixed manufacturing costs.

 

 

 

Net loss for the second quarter of 2024 was $(2.9) million compared to a net loss of $(1.0) million in the second quarter of 2023, which included a loss on marketable securities of ($0.3) million and $(1.6) million in 2024 and 2023, respectively. Net loss was primarily impacted by the dropdown impact of lower revenues. Adjusted EBITDA for the second quarter of 2024 was $1.3 million, compared to $3.9 million in the second quarter of the prior year.

 

Six Months Ended June 30, 2024 Results

 

For the six months ended June 30, 2024, revenues were $47.6 million, compared to $58.7 million in the same period a year ago. Gross margin for the six months ended June 30, 2024 was 58.8% compared with 59.6% in the comparable period of the prior year. Gross profit was $28.0 million for the first half of 2024 compared to $35.0 million in the same period last year. The reduction in gross margin below the Company’s target of 60% was primarily due to lower absorption of fixed manufacturing costs.

 

Net loss for the six months ended June 30, 2024 was ($7.6) million compared to a net loss of $(0.4) million in the same period of 2023, primarily due to the dropdown impact of lower revenues. Adjusted EBITDA for the six months ended June 30, 2024 was $2.9 million, compared to adjusted EBITDA of $8.7 million for the comparable period of 2023.

 

Cash provided by operations was $0.6 million during the six months ended June 30, 2024 compared to $5.4 million in the same period last year.

 

2024 Guidance

 

In light of a delayed market recovery, the Company is reducing its full year 2024 revenue outlook to approximately $97 million to $102 million. The Company expects 2024 full year gross margin of approximately 59% to 60% and adjusted EBITDA margin in the high single digits.

 

Webcast and Conference Call Details

 

In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 10:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to the Company’s Investor Relations website shortly before the webcast begins.

 

Analysts who would like to join the call and ask a question must register here (https://edge.media-server.com/mmc/p/d3g5cbbp). Once registered, you will receive the dial-in numbers and a unique PIN number.

 

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here (https://investor.harvardbioscience.com/events-and-presentations).

 

Use of Non-GAAP Financial Information

 

In this press release, we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, other operating expenses, loss on equity securities, income taxes, and the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.

 

 

 

Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press release.

 

With respect to non-GAAP forward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.

 

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

 

About Harvard Bioscience

 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

 

Forward-Looking Statements

 

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, the strength of the Company’s market position and business model and anticipated macroeconomic conditions. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

 

 

 

 

Company Contact:  Investors Contact:
Jennifer Cote  Three Part Advisors
Chief Financial Officer  Sandy Martin
(508) 893-3120  HBIO@threepa.com
   (214) 616-2207

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HARVARD BIOSCIENCE, INC.

Consolidated Statements of Operations

(unaudited, in thousands, except per share data)

 

   Three Months Ended  Six Months Ended
   June 30, 2024  June 30, 2023  June 30, 2024  June 30, 2023
             
Revenues  $23,097   $28,759   $47,609   $58,734 
Cost of revenues   9,879    12,086    19,619    23,715 
Gross profit   13,218    16,673    27,990    35,019 
                     
Operating expenses:                    
Sales and marketing expenses   5,395    6,178    11,299    12,156 
General and administrative expenses   5,686    5,353    11,649    11,687 
Research and development expenses   2,626    2,957    5,511    5,854 
Amortization of intangible assets   1,331    1,389    2,664    2,777 
Other operating expenses   249    -    1,215    - 
Total operating expenses   15,287    15,877    32,338    32,474 
                     
Operating (loss) income   (2,069)   796    (4,348)   2,545 
                     
Other income (expense):                    
Interest expense   (749)   (941)   (1,500)   (1,915)
Loss on equity securities   (281)   (1,581)   (1,593)   (1,581)
Other (expense) income, net   (181)   (372)   (323)   60 
Total other expense   (1,211)   (2,894)   (3,416)   (3,436)
Loss before income taxes   (3,280)   (2,098)   (7,764)   (891)
Income tax benefit   (353)   (1,118)   (143)   (533)
Net loss  $(2,927)  $(980)  $(7,621)  $(358)
                     
Loss per common share:                    
Basic and diluted  $(0.07)  $(0.02)  $(0.18)  $(0.01)
                     
Weighted-average common shares:                    
Basic and diluted   43,486    42,354    43,443    42,204 

 

 

 

 

 

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Balance Sheets

(unaudited, in thousands)

 

   June 30, 2024  December 31, 2023
Assets          
Cash and cash equivalents  $4,048   $4,283 
Accounts receivable, net   12,486    16,099 
Inventories   25,130    24,716 
Other current assets   4,766    3,940 
Total current assets   46,430    49,038 
Property, plant and equipment   4,758    3,981 
Goodwill and other intangibles   70,068    73,101 
Other long-term assets   7,656    11,246 
Total assets  $128,912   $137,366 
           
Liabilities and Stockholders' Equity          
Current portion, long-term debt  $3,720   $5,859 
Other current liabilities   18,901    20,683 
Total current liabilities   22,621    26,542 
Long-term debt, net   31,960    30,704 
Other long-term liabilities   7,084    7,046 
Stockholders’ equity   67,247    73,074 
Total liabilities and stockholders’ equity  $128,912   $137,366 

 

 

 

 

 

 

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited, in thousands)

 

   Six Months Ended
   June 30, 2024  June 30, 2023
Cash flows from operating activities:          
Net loss  $(7,621)  $(358)
Adjustments to operating cash flows   8,048    7,101 
Changes in operating assets and liabilities   130    (1,379)
Net cash provided by operating activities   557    5,364 
           
Cash flows from investing activities:          
Additions to property, plant and equipment   (1,463)   (741)
Acquisition of intangible assets   (223)   (108)
Proceeds from sale of product line   -    512 
Proceeds from sale of marketable equity securities   1,919    - 
Net cash provided by (used in) investing activities   233    (337)
           
Cash flows from financing activities:          
Borrowing from revolving line of credit   5,550    2,500 
Repayment of revolving line of credit   (2,550)   (5,450)
Repayment of term debt   (4,023)   (2,591)
Proceeds from exercise of employee stock options and purchases   204    724 
Taxes paid related to net share settlement of equity awards   (59)   (451)
Net cash used in financing activities   (878)   (5,268)
           
Effect of exchange rate changes on cash and cash equivalents   (147)   57 
Decrease in cash and cash equivalents   (235)   (184)
Cash and cash equivalents at the beginning of period   4,283    4,508 
Cash and cash equivalents at the end of period  $4,048   $4,324 

 

 

 

 

 

 

HARVARD BIOSCIENCE, INC.

Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)

(in thousands, except per share data and percentages)

 

   Three Months Ended  Six Months Ended
   June 30, 2024  June 30, 2023  June 30, 2024  June 30, 2023
             
GAAP operating (loss) income  $(2,069)  $796   $(4,348)  $2,545 
Stock-based compensation   1,278    1,102    2,326    2,255 
Acquired asset depreciation & amortization   1,338    1,398    2,676    2,798 
Other operating expenses (1)   271    -    1,335    - 
Other adjustments   -    276    -    408 
Adjusted operating income  $818   $3,572   $1,989   $8,006 
                     
Operating margin   (9.0%)   2.8%   (9.1%)   4.3%
Adjusted operating margin   3.5%   12.4%   4.2%   13.6%
                     
                     
GAAP net loss  $(2,927)  $(980)  $(7,621)  $(358)
Stock-based compensation   1,278    1,102    2,326    2,255 
Acquired asset depreciation & amortization   1,338    1,398    2,676    2,798 
Other operating expenses (1)   271    -    1,335    - 
Other adjustments   -    367    -    4 
Loss on equity securities   280    1,581    1,593    1,581 
Income taxes   (36)   (1,776)   591    (2,115)
Adjusted net income   204    1,692    900    4,165 
Depreciation & amortization   464    328    907    649 
Interest and other expense, net   929    1,222    1,822    2,258 
Adjusted income taxes (2)   (317)   658    (734)   1,582 
Adjusted EBITDA  $1,280   $3,900   $2,895   $8,654 
Adjusted EBITDA margin   5.5%   13.6%   6.1%   14.7%
                     
                     
Diluted loss per share (GAAP)  $(0.07)  $(0.02)  $(0.18)  $(0.01)
                     
Diluted adjusted earnings per share  $0.00   $0.04   $0.02   $0.09 
Weighted-average common shares:                    
Diluted GAAP   43,486    42,354    43,443    42,204 
Diluted Adjusted   44,450    44,656    44,516    44,020 
                     

 

(1) Other operating expenses for the three months ended June 30, 2024 includes a credit of $(0.1) million related to an unclaimed property audit and $0.4 million of restructuring-related charges.  Other operating expenses for the six months ended June 30, 2024 includes a $0.5 million commission fee paid in connection with the receipt of employee retention credits, a loss of $0.3 million related to an unclaimed property audit, and $0.4 million of restructuring-related charges.

(2) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.

 

 

 

   June 30, 2024  December 31, 2023
Debt, including unamortized deferred financing costs  $35,680   $36,563 
Unamortized deferred financing costs   420    560 
Cash and cash equivalents   (4,048)   (4,283)
Net debt  $32,052   $32,840 

 

 

 

 

 EX-101.SCH 3 hbio-20240808.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hbio-20240808_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hbio-20240808_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 logo.jpg GRAPHIC begin 644 logo.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Aug. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 08, 2024
Entity File Number 001-33957
Entity Registrant Name HARVARD BIOSCIENCE, INC.
Entity Central Index Key 0001123494
Entity Tax Identification Number 04-3306140
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 84 October Hill Road
Entity Address, City or Town Holliston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01746
City Area Code (508)
Local Phone Number 893-8999
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol HBIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_080824.htm hbio-20240808.xsd hbio-20240808_lab.xml hbio-20240808_pre.xml logo.jpg http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_080824.htm": { "nsprefix": "hbio", "nsuri": "http://globenewswire.com/20240808", "dts": { "inline": { "local": [ "f8k_080824.htm" ] }, "schema": { "local": [ "hbio-20240808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "hbio-20240808_lab.xml" ] }, "presentationLink": { "local": [ "hbio-20240808_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_080824.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_080824.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001171843-24-004562-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-004562-xbrl.zip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ǧ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end XML 17 f8k_080824_htm.xml IDEA: XBRL DOCUMENT 0001123494 2024-08-08 2024-08-08 iso4217:USD shares iso4217:USD shares false 0001123494 8-K 2024-08-08 HARVARD BIOSCIENCE, INC. DE 001-33957 04-3306140 84 October Hill Road Holliston MA 01746 (508) 893-8999 false false false false Common Stock, $0.01 par value HBIO NASDAQ false